Voyager Therapeutics (VYGR) Interest Expenses (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Interest Expenses data on file, last reported at $40.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 2666.18% year-over-year to $40.2 million; the trailing twelve-month figure through Mar 2026 stood at $40.2 million (up 2666.18% YoY), and the FY2025 full-year result was $145.4 million, up 37.32% from the prior year.
• Interest Expenses fell to $40.2 million in Q1 2026, from $145.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $145.4 million in Q4 2025 to a low of $91000.0 in Q4 2022.
• A 5-year average of $25.3 million and a median of $9.5 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 99.92% in 2022 and jumped 90682.42% in 2023, its largest moves.
• Tracing VYGR's Interest Expenses over 5 years: stood at $91000.0 in 2022, then jumped by 90682.42% to $82.6 million in 2023, then sank by 98.49% to $1.3 million in 2024, then jumped by 11524.78% to $145.4 million in 2025, then slumped by 72.38% to $40.2 million in 2026.
• Business Quant data shows VYGR's Interest Expenses at $40.2 million in Q1 2026, $145.4 million in Q4 2025, and $8.0 million in Q3 2025.